Delays out of CHM's control, the whole sector is affected, no blame on CHM. The bright side is the low sp. Those who are patient will make a fortune here over the coming years, financial foundation is built now, not when sp hits the $ range.
Great to see there is progress, let's hope for first patient dosed soon. Soon the worldwide CD19 success story will add the CD17-CDH17 success story to it.
GLTA
Ann: Completion of Viral Vector Manufacturing for Phase 1 trial, page-2
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| CHM (ASX) Chart |
Day chart unavailable